CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges

The therapeutic landscape of multiple myeloma (MM) has benefited from an emergence of novel therapies over the last decade. By inducing T-cell kill of target cancer cells, chimeric antigen receptor (CAR) T-cell therapies have improved outcomes of patients with hematologic malignancies. B-cell matura...

Descripción completa

Detalles Bibliográficos
Autores principales: Rendo, Matthew J, Joseph, Jacinth J, Phan, Liem Minh, DeStefano, Christin B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439649/
https://www.ncbi.nlm.nih.gov/pubmed/36060553
http://dx.doi.org/10.2147/BLCTT.S327016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439649/
https://www.ncbi.nlm.nih.gov/pubmed/36060553
http://dx.doi.org/10.2147/BLCTT.S327016

Ejemplares similares